News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alexion Pharmaceuticals Inc. (ALXN) Research to be Presented at the American Transplant Congress Examines the Role of Terminal Complement Inhibition in the Treatment of Kidney Transplantation Patients


4/30/2010 9:17:51 AM

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers are scheduled to present clinical and laboratory research on the role of terminal complement inhibition therapy in kidney transplantation patients at high risk for antibody-mediated rejection (AMR) at the American Transplant Congress, being held May 1 to 5, 2010, in San Diego. This research includes interim results from an investigator-initiated study of SolirisĀ® (eculizumab) for the prevention of AMR in kidney transplantation patients.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES